Hypertension is the most prevalent modifiable risk factor for cardiovascular disease. This Expert Recommendation, highlights the key consensus recommendations from two guidelines & aim to help health­care professionals.

Read full article (July 2025 Nature Reviews Cardiology) here! 

Heart failure (HF) is not confined to contractile failure of cardiomyocytes or myocardial fibrosis. This Review, provides a mechanistic framework of vascular dysfunction in the pathogenesis of HF, pointing towards integrated therapies that consider the vascular implications of contemporary HF management across HF phenotypes.

Read full article ( Nat Rev Cardiol. 2025 Jun 22) here!

Despite universal coverage, inequities persist in acute coronary syndrome (ACS) care. This study examines how educational levels impact the quality and outcomes of health care.

Read full article (Eur J Clin Invest. 2025;00:e70097) here!

Recent advances in artificial intelligence (AI) have shown great potential in improving cardiovascular pharmacotherapy. This manuscript aims at systematically reviewing the current state-of-the-art applications of AI in cardiovascular pharmacotherapy...

Read full article (European Heart Journal (2025) 00, 1–12) here!

Despite advances in research and patient management, atherosclerosis and its dreaded acute and chronic sequelae continue to account for one out of three deaths globally. A more individualized approach to patients with ACS is advocated...

Read full article (European Heart Journal (2025) 00, 1–24) here!

Starting in the last century, the ability of physicians to provide effective care progressed immensely and accordingly an increasing number of specialities evolved out of the overarching entity ‘internal medicine’.

Read full article (European Heart Journal (2025) 00, 1–4) here!
 

Continuously improving cancer-specific survival puts a growing proportion of cancer patients at risk of major adverse cardiovascular events (MACE). Traditional cardiovascular risk factors and selected cancer types were linked to higher MACE risk. 

Read full article ( J Thromb Haemost. 2024 Nov;22(11):3125-3136) here!

In prospectively recruited patients with ACS, initial BT shows a U- shaped relationship with 1- year MACE risk among those with NSTE- ACS, but not in those with STEMI. 

Read full article (Eur J Clin Invest. 2024 Dec;54(12):e14314) here!

Cardiovascular diseases remain the leading cause of global morbidity and mortality. The paper reviews the role of ML in advancing cardiovascular risk assessment and discuss its potential to identify novel therapeutic targets and to improve prevention strategies. 

Read full article (Eur J Clin Invest. 2025;55(Suppl. 1):e70017) here!

An international consortium, including Dr. Florian A. Wenzl from the CMC, has published new insights in The Lancet Respiratory Medicine on optimising trial design for the personalised management of cardiogenic shock. 

Learn more about this Position Paper (Lancet Respir Med. 2025 May 5) here!